Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment

被引:7
作者
Dedemadi, Anastasia-Georgia [1 ,2 ]
Gkolfinopoulou, Christina [1 ]
Nikoleri, Dimitra [3 ,4 ]
Nikoloudaki, Myrto [3 ]
Ruhanen, Hanna [5 ,6 ,7 ]
Holopainen, Minna [5 ,6 ,7 ]
Kakela, Reijo [6 ,7 ]
Christopoulou, Georgia [8 ]
Bournazos, Stavros [8 ]
Constantoulakis, Pantelis [8 ]
Sidiropoulos, Prodromos [3 ,4 ]
Bertsias, George [3 ,4 ]
Chroni, Angeliki [1 ]
机构
[1] Natl Ctr Sci Res Demokritos, Inst Biosci & Applicat, Athens 15341, Greece
[2] Natl & Kapodistrian Univ Athens, Dept Chem, Athens, Greece
[3] Univ Crete, Med Sch, Lab Rheumatol Autoimmun & Inflammat, Iraklion, Greece
[4] FORTH, Inst Mol Biol & Biotechnol, Iraklion, Greece
[5] Univ Helsinki, Helsinki Inst Life Sci, Lipid Unit, HiLIPID, Helsinki, Finland
[6] Bioctr Finland, Helsinki, Finland
[7] Univ Helsinki, Fac Biol & Environm Sci, Mol & Integrat Biosci Res Program, Helsinki, Finland
[8] Genotypos Sci Labs, Athens, Greece
关键词
systemic lupus erythematosus; biologicals; high-density lipoprotein; atheroprotection; lipidomic profile; CHOLESTEROL EFFLUX CAPACITY; ATHEROSCLEROSIS; FUNCTIONALITY;
D O I
10.1093/rheumatology/keae192
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Chronic inflammatory diseases, like Systemic Lupus Erythematosus (SLE), carry an increased risk for atherosclerosis and cardiovascular events, accompanied by impairment of atheroprotective properties of high-density lipoprotein (HDL). In SLE, serum B cell-activating factor (BAFF), a cytokine implicated in disease progression, has been correlated with subclinical atherosclerosis. We investigated the impact of treatment with belimumab -an anti-BAFF monoclonal antibody- on HDL atheroprotective properties and composition in SLE patients.Methods Serum samples were collected from 35 SLE patients with active disease despite conventional therapy, before and after 6-month add-on treatment with belimumab, and 26 matched healthy individuals. We measured cholesterol efflux and antioxidant capacities, paraoxonase-1 (PON1) activity, serum amyloid A1 (SAA1), myeloperoxidase (MPO) and lipid peroxidation product levels of HDL. LC-MS/MS was performed to analyse the HDL lipidome.Results Following treatment with belimumab, cholesterol efflux and antioxidant capacities of HDL were significantly increased in SLE patients and restored to levels of control subjects. HDL-associated PON1 activity was also increased, whereas lipid peroxidation products were decreased following treatment. HDL cholesterol efflux and antioxidant capacities correlated negatively with the disease activity. Changes were noted in the HDL lipidome of SLE patients following belimumab treatment, as well as between SLE patients and healthy individuals, and specific changes in lipid species correlated with functional parameters of HDL.Conclusions HDL of SLE patients with active disease displays impaired atheroprotective properties accompanied by distinct lipidomic signatures compared with controls. Belimumab treatment may improve the HDL atheroprotective properties and modify the HDL lipidomic signature in SLE patients, thus potentially mitigating atherosclerosis development. Graphical Abstract
引用
收藏
页码:648 / 657
页数:10
相关论文
共 50 条
[31]   BELIMUMAB FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS IN REAL WORLD: A SINGLE CENTER STUDY [J].
Fragio Gil, J. J. ;
Martinez Calabuig, P. ;
Salvador Maicas, L. ;
Gonzalez Mazario, R. ;
Rueda, A. ;
Lerma, J. J. ;
Molina Almela, C. ;
Pastor Cubillo, M. D. ;
Campos Fernandez, C. .
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 :1478-1478
[32]   Effect of belimumab in patients with systemic lupus erythematosus treated with low dose or no corticosteroids [J].
Lee, Yeo-Jin ;
Ahn, Soo Min ;
Hong, Seokchan ;
Oh, Ji-Seon ;
Lee, Chang-Keun ;
Yoo, Bin ;
Kim, Yong-Gil .
KOREAN JOURNAL OF INTERNAL MEDICINE, 2024, 39 (02) :338-346
[33]   Successful application of belimumab in two patients with systemic lupus erythematosus experiencing a flare during tocilizumab treatment [J].
Jueptner, M. ;
Zeuner, R. ;
Schreiber, S. ;
Laudes, M. ;
Schroeder, J. O. .
LUPUS, 2014, 23 (04) :428-430
[34]   Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus [J].
Miyazaki, Yusuke ;
Nakayamada, Shingo ;
Sonomoto, Koshiro ;
Akio, Kawabe ;
Inoue, Yoshino ;
Okubo, Naoaki ;
Iwata, Shigeru ;
Hanami, Kentaro ;
Tanaka, Yoshiya .
RHEUMATOLOGY, 2022, 61 (09) :3614-3626
[35]   Population Pharmacokinetics of Belimumab Following Intravenous Administration in Patients With Systemic Lupus Erythematosus [J].
Struemper, Herbert ;
Chen, Cecil ;
Cai, Wendy .
JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (07) :711-720
[36]   Alopecia areata in patients with systemic lupus erythematosus treated with belimumab: a plausible association [J].
Shamriz, O. ;
Yahia, S. H. ;
Ramot, Y. ;
Agmon-Levin, N. ;
Tal, Y. .
LUPUS, 2020, 29 (04) :426-430
[37]   Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain [J].
Cevey, Maria ;
Calvo-Alen, Jaime ;
Crespo, Carlos ;
Robles-Marhuenda, Angel ;
Smolen, Lee ;
Cortes-Hernandez, Josefina .
CLINICOECONOMICS AND OUTCOMES RESEARCH, 2019, 11 :757-765
[38]   Favorable pregnancy outcomes in two patients with systemic lupus erythematosus treated with belimumab [J].
Wei, Si-Ru ;
Zhu, Zhen-Zhen ;
Xu, Jia ;
Mo, Han-You .
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (01) :154-156
[39]   Serum lipoprotein(a) level and its clinical significance in patients with systemic lupus erythematosus [J].
Sari, RA ;
Polat, MF ;
Taysi, S ;
Bakan, E ;
Çapoglu, I .
CLINICAL RHEUMATOLOGY, 2002, 21 (06) :520-524
[40]   Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients [J].
Formiga, F ;
Meco, JF ;
Pinto, X ;
Jacob, J ;
Moga, I ;
Pujol, R .
LUPUS, 2001, 10 (05) :359-363